{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:49Z","timestamp":1793896489219,"version":"4.8.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The value of measurable residual disease (MRD) in elderly patients with acute myeloid leukemia (AML) is inconsistent between those treated with intensive vs hypomethylating drugs, and unknown after semi-intensive therapy. We investigated the role of MRD in refining complete remission (CR) and treatment duration in the phase 3 FLUGAZA clinical trial, which randomized 283 elderly AML patients to induction and consolidation with fludarabine plus cytarabine (FLUGA) vs 5-azacitidine. After consolidation, patients continued treatment if MRD was \u22650.01% or stopped if MRD was &amp;lt;0.01%, as assessed by multidimensional flow cytometry (MFC). On multivariate analysis including genetic risk and treatment arm, MRD status in patients achieving CR (N = 72) was the only independent prognostic factor for relapse-free survival (RFS) (HR, 3.45;\u00a0P\u00a0= .002). Achieving undetectable MRD significantly improved RFS of patients with adverse genetics (HR, 0.32;\u00a0P\u00a0= .013). Longer overall survival was observed in patients with undetectable MRD after induction though not after consolidation. Although leukemic cells from most patients displayed phenotypic aberrancies vs their normal counterpart (N = 259 of 265), CD34 progenitors from cases with undetectable MRD by MFC carried extensive genetic abnormalities identified by whole-exome sequencing. Interestingly, the number of genetic alterations significantly increased from diagnosis to MRD stages in patients treated with FLUGA vs 5-azacitidine (2.2-fold vs 1.1-fold;\u00a0P\u00a0= .001). This study supports MRD assessment to refine CR after semi-intensive therapy or hypomethylating agents, but unveils that improved sensitivity is warranted to individualize treatment and prolong survival of elderly AML patients achieving undetectable MRD.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003195","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T21:35:51Z","timestamp":1612647351000},"page":"760-770","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial"],"prefix":"10.1182","volume":"5","author":[{"given":"Catia","family":"Simoes","sequence":"first","affiliation":[{"name":"Department of Hematology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain;"},{"name":"Centro de Investigaci\u00f3n Medica Aplicada (CIMA), Pamplona, Spain;"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Navarra (IDISNA), Pamplona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain;"},{"name":"Centro de Investigaci\u00f3n Medica Aplicada (CIMA), Pamplona, Spain;"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Navarra (IDISNA), Pamplona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-4091","authenticated-orcid":false,"given":"David","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"additional","affiliation":[{"name":"Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8229-1208","authenticated-orcid":false,"given":"Juan-Miguel","family":"Bergua","sequence":"additional","affiliation":[{"name":"Hospital San Pedro de Alc\u00e1ntara, C\u00e1ceres, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Vives","sequence":"additional","affiliation":[{"name":"Instituto Catal\u00e1n de Oncolog\u00eda (ICO), Hospital Germans Trias i Pujol, Badalona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Algarra","sequence":"additional","affiliation":[{"name":"Hospital General de Albacete, Albacete, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Tormo","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Martinez","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Serrano","sequence":"additional","affiliation":[{"name":"Hospital Reina Sof\u00eda, Cordoba, Spain;"},{"name":"Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC), Cordoba, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Herrera","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-2655","authenticated-orcid":false,"given":"Fernando","family":"Ramos","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Le\u00f3n, L\u00e9on, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-0025","authenticated-orcid":false,"given":"Olga","family":"Salamero","sequence":"additional","affiliation":[{"name":"Hospital Universitario Vall d\u2019Hebr\u00f3n, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-0678","authenticated-orcid":false,"given":"Esperanza","family":"Lavilla","sequence":"additional","affiliation":[{"name":"Hospital Lucus Augusti, Lugo, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gil","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Alicante, Alicante, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Luis","family":"Lopez","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-3673","authenticated-orcid":false,"given":"Maria-Belen","family":"Vidriales","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Salamanca, Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Labrador","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Burgos, Burgos, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Francisco","family":"Falantes","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Virgen del Rocio, Seville, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Jos\u00e9","family":"Sayas","sequence":"additional","affiliation":[{"name":"University Hospital Dr Peset, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-8353","authenticated-orcid":false,"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[{"name":"Instituto de Investigacion 12 de Octubre, Hospital Universitario 12 de Octubre, Madrid, Spain;"},{"name":"Universidad Complutense, Madrid, Spain;"},{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Villar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain;"},{"name":"Centro de Investigaci\u00f3n Medica Aplicada (CIMA), Pamplona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jose","family":"Calasanz","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Medica Aplicada (CIMA), Pamplona, Spain;"},{"name":"Department of Biochemistry, University of Navarra, Navarra, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-8790","authenticated-orcid":false,"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain;"},{"name":"Centro de Investigaci\u00f3n Medica Aplicada (CIMA), Pamplona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jes\u00fas F.","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain;"},{"name":"Centro de Investigaci\u00f3n Medica Aplicada (CIMA), Pamplona, Spain;"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Navarra (IDISNA), Pamplona, Spain;"},{"name":"\u00c1rea de Oncolog\u00eda del Instituto de Salud Carlos III, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBER-ONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1489-1177","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Sanz","sequence":"additional","affiliation":[{"name":"Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[{"name":"Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"issue":"18","key":"2021020421350992900_B1","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2021020421350992900_B2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2021020421350992900_B3","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"22","key":"2021020421350992900_B4","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2021020421350992900_B5","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2021020421350992900_B6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/cancers10070215","article-title":"Role of minimal (measurable) residual disease assessment in older patients with acute myeloid leukemia","volume":"10","author":"Buccisano","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2021020421350992900_B7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"12","key":"2021020421350992900_B8","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"2021020421350992900_B9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2017.285","article-title":"Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse","volume":"32","author":"Boddu","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2021020421350992900_B10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2021020421350992900_B11","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021020421350992900_B12","first-page":"439","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008","edition":"4th ed"},{"issue":"3","key":"2021020421350992900_B13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2021020421350992900_B14","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"issue":"20","key":"2021020421350992900_B15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","article-title":"Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia","volume":"135","author":"Hasserjian","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2021020421350992900_B16","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nprot.2009.86","article-title":"Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm","volume":"4","author":"Kumar","year":"2009","journal-title":"Nat Protoc"},{"issue":"10","key":"2021020421350992900_B17","doi-asserted-by":"crossref","first-page":"e46688","DOI":"10.1371\/journal.pone.0046688","article-title":"Predicting the functional effect of amino acid substitutions and indels","volume":"7","author":"Choi","year":"2012","journal-title":"PLoS One"},{"issue":"17","key":"2021020421350992900_B18","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1093\/nar\/gkr407","article-title":"Predicting the functional impact of protein mutations: application to cancer genomics","volume":"39","author":"Reva","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2021020421350992900_B19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","article-title":"MutationTaster2: mutation prediction for the deep-sequencing age","volume":"11","author":"Schwarz","year":"2014","journal-title":"Nat Methods"},{"issue":"9","key":"2021020421350992900_B20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1101\/gr.092619.109","article-title":"Identification of deleterious mutations within three human genomes","volume":"19","author":"Chun","year":"2009","journal-title":"Genome Res"},{"issue":"8","key":"2021020421350992900_B21","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/hmg\/ddu733","article-title":"Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies","volume":"24","author":"Dong","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2021020421350992900_B22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1479-7364-8-11","article-title":"Ranking non-synonymous single nucleotide polymorphisms based on disease concepts","volume":"8","author":"Shihab","year":"2014","journal-title":"Hum Genomics"},{"issue":"12","key":"2021020421350992900_B23","doi-asserted-by":"crossref","first-page":"e1001025","DOI":"10.1371\/journal.pcbi.1001025","article-title":"Identifying a high fraction of the human genome to be under selective constraint using GERP++","volume":"6","author":"Davydov","year":"2010","journal-title":"PLoS Comput Biol"},{"issue":"12","key":"2021020421350992900_B24","doi-asserted-by":"crossref","first-page":"e51422","DOI":"10.1371\/journal.pone.0051422","article-title":"Estimation of copy number alterations from exome sequencing data","volume":"7","author":"Vald\u00e9s-Mas","year":"2012","journal-title":"PLoS One"},{"issue":"18","key":"2021020421350992900_B25","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"issue":"19","key":"2021020421350992900_B26","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1093\/bioinformatics\/btu393","article-title":"circlize implements and enhances circular visualization in R","volume":"30","author":"Gu","year":"2014","journal-title":"Bioinformatics"},{"issue":"4","key":"2021020421350992900_B27","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2021020421350992900_B28","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/cncr.23219","article-title":"Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience","volume":"112","author":"Plesa","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"2021020421350992900_B29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2012.04.008","article-title":"Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype","volume":"44","author":"Dang","year":"2013","journal-title":"Hum Pathol"},{"issue":"11","key":"2021020421350992900_B30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cancergen.2016.10.004","article-title":"Polymorphisms and haplotypes of the CYP2B6 detoxification gene in the predisposition of acute myeloid leukemia (AML) and induction of its cytogenetic abnormalities","volume":"209","author":"Daraki","year":"2016","journal-title":"Cancer Genet"},{"issue":"4","key":"2021020421350992900_B31","doi-asserted-by":"crossref","first-page":"1761243","DOI":"10.1080\/23723556.2020.1761243","article-title":"Targeting neurolysin in acute myeloid leukemia","volume":"7","author":"Mirali","year":"2020","journal-title":"Mol Cell Oncol"},{"issue":"2","key":"2021020421350992900_B32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12032-013-0517-8","article-title":"Deregulation of protein phosphatase expression in acute myeloid leukemia","volume":"30","author":"Kabir","year":"2013","journal-title":"Med Oncol"},{"issue":"2","key":"2021020421350992900_B33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"7","key":"2021020421350992900_B34","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1158\/1078-0432.CCR-17-2344","article-title":"Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: an exome sequencing study of 50 patients","volume":"24","author":"Greif","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2021020421350992900_B35","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00277-015-2364-5","article-title":"Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients","volume":"94","author":"Buccisano","year":"2015","journal-title":"Ann Hematol"},{"issue":"32","key":"2021020421350992900_B36","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia","volume":"31","author":"Freeman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"2021020421350992900_B37","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2021020421350992900_B38","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021020421350992900_B39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021020421350992900_B40","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"issue":"13","key":"2021020421350992900_B41","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/3\/760\/1799446\/advancesadv2020003195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/3\/760\/1799446\/advancesadv2020003195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T12:55:47Z","timestamp":1612788947000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/3\/760\/475085\/Measurable-residual-disease-in-elderly-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003195","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]}}}